Aeterna Zentaris Inc. (AEZS) is a biopharmaceutical company that specializes in manufacturing and distributing therapeutics and tests used for medical diagnosis. The company is also expanding its current development pipeline and clinical trials of macimorelin- which will be used in the diagnosis of a growth hormone deficiency, an area without adequate medical need.
The company Regained agreement with minimum bid price policy for continued listing on Nasdaq and AEZS common shares had a close bought deal for gross capital exceeding $34 million. The company also received $20M in capital from share dilution and using warrants.
AEZS Plans For Pipeline Expansion
AEZS continued to execute its pipeline expansion developing its pre-clinical programs via several licensing agreements with European universities. The Company started an official license agreement with Julius-Maximilians-University of Wuerzburg, Germany, having international patent and rights to produce and advertise, extremely distinct immunosuppressive protein therapeutics expecting treatment for Neuromyelitis Optica spectrum disorder, which has an unmet medical need.
The company also amended its current license with Novo Nordisk for manufacturing Macrilen to penetrate Canadian and American markets. AEZS is currently meeting the concerned medical authorities for confirmation of preclinical data required to advance into human clinical trials.
Production of a Potential Oral Bacterial Vaccine For COVID-19
AEZS has announced to be part of an exclusive international sub-licensable contract for a COVID 19 vaccine which is present in an initial development phase at the Julius-Maximilians-University. The company has a research agreement and is already looking for a pre-clinical trial for the potential vaccine.
The vaccine uses the salmonella strain as an orally active live-attenuated bacteria to prevent COVID 19 improving the immune response against mutated viruses.
Conclusion
AEZS is in the lucrative field of biopharmaceuticals and is keen on research for vaccines of COVID and diseases with unmet medical needs. Savvy financial moves like share dilution and close bought deals have given the company a market capitalization of a staggering $135M and is anticipating a surge in revenue if the covid 19 vaccines produce efficient results.
